Do you believe that the likelihood of generic competition for Angiomax is already priced into the stock valuation, or is it not priced in because it's not a certainty yet?
It’s already priced in, IMO. The stock has been in a downward trend ever since it became clear that MDCO was not going to be able to extend the US patent:
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
AI
